Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the e-BioMatrix PMS registry is to capture clinical data of the BioMatrix (Biolimus A9-Eluting) stent system in relation to safety and effectiveness.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Major adverse cardiac events (MACE) in the overall population, defined as composite of cardiac death, myocardial infarction (Q-wave and non-Q-wave), or justified target vessel revascularization | 12 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Primary and secondary stent thrombosis (definite and probable according to ARC definitions) | 30 days, 6 and 12 months, 2, 3 and 5 years | |
| Major adverse cardiac events (MACE) in the overall population, defined as composite of cardiac death, myocardial infarction (Q-wave and non-Q-wave), or justified target vessel revascularization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
"Real world, all comer" patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Philip Urban, MD | Hôpital de La Tour | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arrixaca University Hospital | Murcia | 30120 | Spain | |||
| Inselspital |
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 30 days, 6 months, 2, 3 and 5 years |
| Patient Oriented Composite Endpoint defined as any cause mortality, MI (Q-wave and non-Q-wave), or any clinically driven target vessel revascularization | 30 days, 6 and 12 months, 2, 3 and 5 years |
| Death and MI | 30 days, 6 and 12 months, 2, 3 and 5 years |
| Total revascularization rate (clinically and non clinically driven) | 30 days, 6 and 12 months, 2, 3 and 5 years |
| Bern |
| 3010 |
| Switzerland |
| Hôpital Cantonal de Fribourg | Fribourg | 1708 | Switzerland |
| Hôpitaux Universitaires de Genève | Geneva | 1211 | Switzerland |
| Cardiocentro Ticino | Lugano | 6900 | Switzerland |
| Hôpital de La Tour | Meyrin | 1217 | Switzerland |
| Triemli Hospital | Zurich | 8063 | Switzerland |
| Brighton-Sussex University Hospitals | Brighton | BN2 5BE | United Kingdom |
| Manchester Heart Center | Manchester | M13 9WL | United Kingdom |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |